- Medical Malpractice
- Product
- Unsafe Drugs
- Bisphosphonate Litigation
- Bextra Litigation
- Silicone Gel Breast Implant Litigation
- Fen-Phen Diet Drugs
- Guidant Defibrillators
- Hormone Replacement Drugs
- Kugel Hernia Mesh Patches
- Medtronic Sprint Fidelis Lead
- Mentor ObTape Trans-Obturator Tape Litigation
- Ortho Evra Birth Control Patch
- Bausch & Lomb's ReNu with MoistureLoc Contact Lens Solution
- Vioxx Litigation
- Shoulder Pain Pumps
- Medtronic Defibrillator Litigation
- Other/Archive Drug Products
- Personal Injuries
- Auto Accidents
- Nursing Home Abuse
Follow-up Study Confirms Risks of HRT Outweigh Benefits
In the March 5, 2008, issue of the Journal of the American Medical Association (JAMA), the results of a three-year follow-up study of the estrogen-plus-progestin clinical trial were published which confirm the health risks of long-term use of combination HRT therapy (estrogen plus progestin) in healthy, postmenopausal women persist even a few years after stopping the drugs and clearly outweigh the benefits. Researchers report that about three years after women stopped taking combination hormone therapy, many of the health effects of hormones such as increased risk of heart disease are diminished, but overall risks, including risks of stroke, blood clots, and cancer, remain high. The WHI is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
Click here to read NIH press release